Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vandefitemcel
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SanBio: Notice Regarding Completion of Approval Filing for Japan SB623 Chronic TBI Program
Details : This application for approval is based on efficacy and safety result of STEMTRA trial for SB623 (vandefitemcel), a human bone marrow-derived modified mesenchymal stem cell, met its primary endpoint achieving statistically significant improvement in motor...
Product Name : SB623
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 03, 2022
Lead Product(s) : Vandefitemcel
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vandefitemcel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Of the 51 patients in the treatment group that received SB623, improvement was seen in 49%, versus in 19% of 26 patients in the control group that received sham surgery, the difference between the two groups was statistically significant.
Product Name : SB623
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 14, 2020
Lead Product(s) : Vandefitemcel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vandefitemcel
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : OcuMension Therapeutics
Deal Size : $71.0 million
Deal Type : Agreement
Details : Ocumension obtains exclusive rights from SanBio to develop and commercialize SB623 and MSC2 in Greater China for ophthalmic indications.
Product Name : SB623
Product Type : Cell and Gene therapy
Upfront Cash : $6.0 million
March 31, 2020
Lead Product(s) : Vandefitemcel
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : OcuMension Therapeutics
Deal Size : $71.0 million
Deal Type : Agreement